Article Details

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton ...

Retrieved on: 2024-05-11 20:00:03

Tags for this article:

Click the tags to see associated articles and topics

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton .... View article details on hiswai:

Summary

Azitra, Inc. announced preclinical data showing ATR-12's potential as a topical treatment for Netherton syndrome by delivering LEKTI protein and reducing IL-36γ, a pro-inflammatory cytokine. The treatment was also safe in minipigs.

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up